CHRS Coherus BioSciences Inc.

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A replay of the webcast will be available on following the conclusion of the live conference call.

Conference Call Information

When: Wednesday, March 13, 2024, starting at 5:00 p.m. Eastern Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call:

Webcast:

The press release with the fourth quarter and full year 2023 financial results and related materials will be available at prior to the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at /events-presentations.

Please dial-in 15 minutes early to ensure a timely connection to the call.

Coherus Contact Information

Investors:

Jami Taylor, Head of Investor Relations for Coherus



EN
05/03/2024

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on  following the conclusion of the live conference call. Conference Call Informat...

May 1, 2024 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Announces Presentation at the 2024 American Society of Clinica...

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Anti...

April 24, 2024 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Anti...

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting – In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy –– First novel immuno-oncology product candidate discovered and developed by Coherus –– The CHS-1000 IND submission is planned for Q2 2024 – REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioScienc...

April 8, 2024 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial R...

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 –  – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 –  – CIMERLI® net sales of $52.4 million in the fourth quarter and $125.4 million in FY 2023 – – LOQTORZI™ and UDENYCA ONBODY™ successfully launched in Q1 2024 –  – Reduction of work force of 30% for 2024 initiated on March 7, 2024 – – Conference call today at 5:00 p.m. Eastern Time – RED...

March 13, 2024 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results ...

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A replay of the webcast will be available on following the conclusion of the l...

March 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch